Experience the World of Easy NGS

The only true end-to-end NGS solution for oncology biomarker profiling in clinical research: Ion Torrent Genexus System

 

 

 

genexus-request-virtual-demo-cta

 

It's NGS as fast and easy as IHC or PCR

Now every lab can go from biological specimen to report in a single day.

 

genexus-benefits-graphic

 

What is truly “end to end” and automated NGS?

Whilst other NGS workflows are advertised as “end to end” and “automated”, we believe that the Ion Torrent™ Genexus™ System and assay menu represents the only true end to end solution at the market. 2 instruments, 1 software and assays, all from one supplier will enable you go from biological specimen to report in as little as 1 day, involving only 20 min hand on time.

 

 
 

What are the benefits of Oncomine NGS Solutions powered by the end-to-end Genexus System?

  • There is only one supplier of all instrumentation and reagents you require which will simplify your purchasing and technology implementation processes
  • Only 2 instrument and 1 software will reduce number of validations, SOPs and need for additional expertise
  • 20 min hands on time will allow your technicians to do other work and reduce potential handling errors
  • Fast turn around time (TAT) will enable you to report complete relevant biomarker profile including results from NGS and IHC or other single gene technologies, fast and at once

Ion Torrent Genexus System

Turnkey end-to-end NGS system that automates the specimen to report workflow and delivers results in a single day.

 

ngs-oncology-workflow-oncomine3


download-flyer-cta

Oncomine Assays for the Genexus System

Genexus News

Read the latest news and user stories about how the Genexus System is advancing precision oncology in our quarterly e-news.

 

Latest News

The Genexus System and Ion Torrent™ Oncomine™ Dx Target Test are expected to comply with CE mark requirements in 2022

In this issue, we bring you a number of new stories, testimonials, and data from Genexus System users. But first, we want to share that we are working hard on making the Genexus System, and a number of next-generation sequencing (NGS) assays, compliant with the new In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746. Read more.

genexus-news-feature-small-nov21

 

read-genexus-news-cta

Genexus Webinar Series

Enjoy this three-part on-demand series that gives you a closer look at the new Genexus System and FusionSync technology

 

Genexus Software - It's a New World

Are you worried about NGS bioinformatics? Using different software and requiring an expert to stich it all together? No need anymore! The Genexus Software, one secure, streamlined and easy-to-use NGS analysis software, provides a seamless experience from end to end, starting with entering sample data and finishing with report.

genexus-request-virtual-demo-cta

 

Oncomine Reporter

The Oncomine Reporter delivers clear and concise reports that present all relevant variants with annotated information about targeted therapies, guidelines, and enrollment of ongoing clinical trials.

The report is customizable so that you can tailor it to fit your team's needs.

Learn More About Oncomine Informatics

report-example-new

 

Watch easy NGS in action

A molecular biology laboratory at the Hospital Universitari Vall d'Hebron performs NGS analysis with the Genexus System.

 

NoInforme_NuevoTitulo (1)

 

 

Molecular Tagging

The Oncomine Precision Assay on the Ion Torrent Genexus System detects low-level variants that are particularly important for liquid biopsy testing. It provides:

  • Enhanced specificity
  • Enhanced sensitivity
  • Artifact detection

Screen Shot 2020-08-27 at 1.42.12 PM

Results from Tissue and Plasma Samples

Although tissue samples are still the gold standard for molecular profiling, there exist many limitations.

Tissue can be inaccessible or there may not be enough material to sequence. Further, obtaining a tissue sample is difficult to repeat and not useful for monitoring and the sample may not reflect tumor heterogeneity. Liquid biopsy may be a viable alternative to tissue sequencing, as it is minimally invasive, provides a comprehensive tumor profile, and allows for repeat sampling.

With the Oncomine Precision Assay, you have the flexibility to sequence standard tissue or minimally invasive plasma samples, from one test on a single workflow.

Screen Shot 2020-08-25 at 2.28.38 PM

Flexible Financing for Every Lab

Now you don’t have to wait to access the Genexus System. We are committed
to supporting your research by offering a wide range of financial and leasing
programs for even easier adoption of NGS.

explore-financing-options-cta

 

Additional Resources

References:

1. Next-Generation Sequencing in 305 Consecutive Patents: Clinical Outcomes and Management Changes; Gregory J. Kubicek, MD., et al., Journal of Clinical Oncology, Aug. 2019.
2. J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.
3. Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer; Jason Zhu, et al.; Urologic Cancer: Seminars and Original Investigations, July 2019.
4. Abstract 4889: Comparison of tumor mutational burden using the Ion Oncomine™ TML and FoundationOne™ assays with routine clinical FFPE tissue samples to predict durable clinical benefit in lung cancer and melanoma patients - a multivariate analysis integrating PD-L1 and CD8+ evaluation. Heeke S. et al. DOI: 10.1158/1538-7445.AM2019-4889; July 2019.

For Research Use Only.  Not for use in diagnostic procedures.